Paper Chase is a research database designed to offer abstracts of research articles published in journals that have a highly rated impact factor as determined by ISI Impact Factor and PageRank. Abstracts are organized by date, with the most recently published papers listed first. 

Paper Chase

41.

An active shooter in our hospital.

Lancet.
Goralnick E, Walls R.
| May 2, 2015
42.

Risk factors for and origins of COPD.

Lancet.
Byrne AL, Marais BJ, Mitnick CD, Lecca L, Marks GB.
| May 2, 2015
43.

Reducing the burden of iatrogenic harm in children.

Lancet.
Carson-Stevens A, Edwards A, Panesar S, Parry G, Rees P, Sheikh A, Donaldson L.
| Apr 25, 2015
44.

The history and fate of the gold standard.

Lancet.
Jones DS, Podolsky SH.
| Apr 18, 2015
45.

Surgical palliative care in resource-limited settings.

Lancet.
Riesel JN, Mandigo M, Gillies R, Damuse R, Farmer PE, Cusack JC, Krakauer EL, Shulman LN.
| Aug 8, 2015
46.

Global surgery--going beyond the Lancet Commission.

Lancet.
Davies JI, Meara JG.
| Aug 8, 2015
47.

Global Surgery 2030: evidence and solutions for achieving health, welfare, and economic development.

Lancet.
Meara JG, Leather AJ, Hagander L, Alkire BC, Alonso N, Ameh EA, Bickler SW, Conteh L, Dare AJ, Davies J, Mérisier ED, El-Halabi S, Farmer PE, Gawande A, Gillies R, Greenberg SL, Grimes CE, Gruen RL, Ismail EA, Kamara TB, Lavy C, Lundeg G, Mkandawire NC, Raykar NP, Riesel JN, Rodas E, Rose J, Roy N, Shrime MG, Sullivan R, Verguet S, Watters D, Weiser TG, Wilson IH, Yamey G, Yip W.
| Aug 8, 2015
48.

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.

Lancet.
Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S, Achenbach C.
| Jun 27, 2015
49.

On the (f)utility of pain.

Lancet.
Stonington SD.
| Apr 11, 2015
50.

Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED II): a prospective, open-label, multicentre, randomised non-inferiority trial.

Lancet.
Ardehali A, Esmailian F, Deng M, Soltesz E, Hsich E, Naka Y, Mancini D, Camacho M, Zucker M, Leprince P, Padera R, Kobashigawa J, Baran D.
| Jun 27, 2015
51.

Diagnosis of reversible causes of coma - Authors' reply.

Lancet.
Edlow JA, Rabinstein A, Traub SJ, Wijdicks EF.
| Mar 28, 2015
52.

The future of WHO: outsourcing?

Lancet.
Dhillon RS.
| Mar 21, 2015
53.

5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial.

Lancet.
Mack MJ, Leon MB, Smith CR, Miller DC, Moses JW, Tuzcu EM, Webb JG, Douglas PS, Anderson WN, Blackstone EH, Kodali SK, Makkar RR, Fontana GP, Kapadia S, Bavaria J, Hahn RT, Thourani VH, Babaliaros V, Pichard A, Herrmann HC, Brown DL, Williams M, Akin J, Davidson MJ, Svensson LG.
| Jun 20, 2015
54.

5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial.

Lancet.
Kapadia SR, Leon MB, Makkar RR, Tuzcu EM, Svensson LG, Kodali S, Webb JG, Mack MJ, Douglas PS, Thourani VH, Babaliaros VC, Herrmann HC, Szeto WY, Pichard AD, Williams MR, Fontana GP, Miller DC, Anderson WN, Akin JJ, Davidson MJ, Smith CR.
| Jun 20, 2015
55.

Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials.

Lancet.
Palmerini T, Benedetto U, Bacchi-Reggiani L, Della Riva D, Biondi-Zoccai G, Feres F, Abizaid A, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Genereux P, Bhatt DL, Orlandi C, De Servi S, Petrou M, Rapezzi C, Stone GW.
| Jun 13, 2015
58.

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.

Lancet.
Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, Deenadayalu N, Jarolim P, Betcher J, Shi M, Brown K, Patel I, Mercuri M, Antman EM.
| Jun 6, 2015
60.

Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.

Lancet.
Mega JL, Walker JR, Ruff CT, Vandell AG, Nordio F, Deenadayalu N, Murphy SA, Lee J, Mercuri MF, Giugliano RP, Antman EM, Braunwald E, Sabatine MS.
| Jun 6, 2015